NVP-1205
AssetAlso Crestor+Ezetrol
Combination inhibiting HMG-CoA reductase and NPC1L1 for lipid lowering.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 1
- Indication
- 684
- Trials
- 1
- Developer
Indications
1Dyslipidemia
Phase 1, Completed, NCT02029625, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains5
- Owner and partners1
- Trials684
- Evidence for its targets5
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.